In the Phase 3 REZILIENT 3 trial, adding zipalertinib to platinum-pemetrexed extended median progression-free survival in advanced NSCLC with EGFR exon 20 insertion mutations. The company reported a rise in median PFS from 8.5 months to 14.5 months as first-line therapy. The data reinforce the expanding set of targeted options for EGFR exon 20 insertion disease, where prior outcomes have often been limited by heterogeneous sensitivity. The trial design also highlights the continuing strategy of combining targeted drugs with established chemotherapy backbones. For drug developers, the readout adds urgency to how companies benchmark next-line sequencing and endpoints in mutation-defined NSCLC populations as treatment landscapes rapidly evolve.